• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » laViv (azficel-T)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

laViv (azficel-T)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    laViv (azficel-T) is an autologous cellular product. Collagen-producing fibroblast cells are harvested from the skin behind the ear. The fibroblasts from this tissue sample are cultured and allowed to multiply, so they can be injected to treat appropriate dermal targets. The exact mechanism of action is unknown.

    laViv is specifically indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

    laViv is for autologous intradermal injection only. The recommended treatment regimen is three treatment sessions, administering up to 2 milliliters (2 vials) of laViv per session, at three to six week intervals.

    Clinical Results

    FDA Approval
    The FDA approval of laViv was based on two identicall multi-center, randomized, double-blind, placebo controlled studies. The trial enrolled 421 subjects 23 to 81 years with moderate to severe bilateral nasolabial fold wrinkles. Each subject underwent three post-auricular skin punch biopsies to obtain skin tissue to generate laViv. Subjects whose biopsy samples met acceptance criteria were randomized to receive either laViv or placebo administered intradermally to nasolabial fold wrinkles on both sides of the face. A total of three separate treatment sessions occurred at intervals of approximately five weeks. For both clinical trials, the co-primary efficacy outcomes were the proportion of subjects with a two-point improvement from baseline in the appearance of the nasolabial fold wrinkles at six months after the third treatment session, assessed independently by subjects and by evaluating physicians. Subjects assessed their nasolabial fold wrinkles on a five-point Subject Wrinkle Assessment scale that ranged from -2 to +2. The evaluating physicians used a six-point Evaluator Wrinkle Severity Assessment scale that ranged from 0 to 5. When subjects assessed themselves, 57% (Study One) and 45% (Study Two) of subjects receiving laViv achieved a 2-point improvement in the appearance of their nasolabial fold wrinkles compared with 30% (Study One) and 18% (Study Two) of subjects receiving placebo control. When assessed by evaluating physicians, 33% (Study One) and 19% (Study Two) of subjects receiving laViv achieved a 2-point improvement in their nasolabial fold wrinkles, compared with 7% of subjects receiving vehicle-control in both trials.

    Side Effects

    Adverse events associated with the use of laViv may include, but are not limited to, the following:

    • injection-site redness
    • bruising
    • swelling
    • pain
    • hemorrhage
    • edema
    • nodules
    • papules
    • irritation
    • dermatitis
    • pruritus

    Mechanism of Action

    laViv (azficel-T) is an autologous cellular product. Collagen-producing fibroblast cells are harvested from the skin behind the ear. The fibroblasts from this tissue sample are cultured and allowed to multiply, so they can be injected to treat appropriate dermal targets. The exact mechanism of action is unknown.

    Additional Information

    For additional information regarding laViv or nasolabial fold wrinkles, please visit the laViv web page.

    Approval Date: 2011-06-01
    Company Name: Fibrocell Science
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing